Drug intelligence / Profile preview

Neuralgin

Development stage
Unknown
Lead developer
Dr. Pfleger
Modality
Small Molecules
Administration
Oral
01

Overview

Neuralgin is an over-the-counter (OTC) analgesic combination product developed and manufactured by Dr. Pfleger Arzneimittel. It is formulated as a tablet containing three active ingredients: acetylsalicylic acid (aspirin), paracetamol (acetaminophen), and caffeine. Acetylsalicylic acid and paracetamol provide analgesic and antipyretic effects through the inhibition of cyclooxygenase enzymes, while caffeine acts as an adjuvant to enhance and accelerate the pain-relieving action. The product is primarily indicated for the treatment of acute mild to moderate pain, including tension headaches, migraine attacks (with and without aura), and fever. It is approved for use in adults and adolescents aged 12 years and older and is widely available in pharmacies across Germany.

Brand names
NeuralginNeuralgin Schmerztabletten
Other names
Neuralgin Schmerztabletten
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Neuralgin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuralgin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call